Researchers at the Keck School of Medicine have identified a variant in the genome that may explain why multiple men in the same family develop the disease—and could serve as a guide for screening,
For years, researchers have known that men of African ancestry are at greater risk of developing prostate cancer with research suggesting that inherited factors may contribute to their greater risk.
Now, a new USC study published in European Urology is the first to identify an inherited genetic variant associated with higher risk of prostate cancer in men of African descent that contributes to the clustering of prostate cancer cases within families.
“About 12% of men of African ancestry carry this particular variant in the genome, which increases their risk two-fold. The variant is not found in other populations,” Christopher Haiman, study author and professor of preventive medicine, Keck School of Medicine of USC, said in a statement. “But it’s even more common in families with a history of prostate cancer.”
One in six African American men develops prostate cancer in his lifetime. African American men are 1.8 times more likely to be diagnosed with—and 2.2 times more likely to die from—prostate cancer than white men. If a black man’s brother or father had prostate cancer, his risk will be even higher.
Until now, there has been no genetic mutation or biomarker doctors could look for to determine if a particular African American man was more likely to get the disease.
While a prostate specific-antigen blood test can detect prostate cancer, many of the cancers it detects may not cause harm, while treatment can cause life-altering side effects.
In the study, which is part of the RESPOND African American prostate cancer initiative, researchers looked at 9,052 prostate cancer cases among men of African ancestry. More than 23% had this specific genetic variant. The variant was strongly associated with a prostate cancer diagnosis at an earlier age, more aggressive disease, and men with a family history of prostate cancer. In fact, 32% of the men with prostate cancer who had a family history of the disease carried the variant.
This new information may eventually help clinicians identify men who could benefit from early prostate cancer screening and treatment.
“A man of African ancestry comes in and says, ‘Well, I have prostate cancer and I have a family history of the disease. Why?’ Well, now there’s a variant you can test to see if they and their family members carry it,” Haiman said. “This is a marker that down the road may be used to identify African-Americans and their family members who are at high risk and would benefit from more precise, targeted, and earlier PSA screening.”
Researchers believe this variant is one of the reasons why African American men are more likely to get prostate cancer and hope to find out more about the role genetic mutations play in their overall risk.